User profiles for "author:Spyridon Deftereos"

Spyridon Deftereos

National and Kapodistrian University of Athens, Medical School
Verified email at med.uoa.gr
Cited by 22737

Colchicine in cardiovascular disease: in-depth review

SG Deftereos, FJ Beerkens, B Shah, G Giannopoulos… - Circulation, 2022 - Am Heart Assoc
Inflammation plays a prominent role in the development of atherosclerosis and other
cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular …

Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials

AH Katsanos, A Filippatou, E Manios, S Deftereos… - …, 2017 - Am Heart Assoc
Current recommendations do not specifically address the optimal blood pressure (BP)
reduction for secondary stroke prevention in patients with previous cerebrovascular events …

Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease

N Anatoliotakis, S Deftereos, G Bouras… - Current topics in …, 2013 - ingentaconnect.com
Myeloperoxidase (MPO), a heme protein released by leukocytes, is one of the most widely
studied during the last decades molecule that plays a crucial role in inflammation and …

2019 ESC guidelines for the management of patients with supraventricular tachycardia the task force for the management of patients with supraventricular tachycardia …

J Brugada, DG Katritsis, E Arbelo, F Arribas… - European heart …, 2020 - academic.oup.com
Supraventricular arrhythmias are common and patients are often symptomatic, requiring
management with drugs and electrophysiological procedures. The ESC published …

Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the …

SG Deftereos, G Giannopoulos, DA Vrachatis… - JAMA network …, 2020 - jamanetwork.com
Importance Severe acute respiratory syndrome coronavirus 2 infection has evolved into a
global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable …

[HTML][HTML] Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre …

JC Tardif, N Bouabdallaoui, PL L'allier… - The Lancet …, 2021 - thelancet.com
Background Evidence suggests a role for excessive inflammation in COVID-19
complications. Colchicine is an oral anti-inflammatory medication beneficial in gout …

Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action

I Rentoukas, G Giannopoulos, A Kaoukis… - JACC: Cardiovascular …, 2010 - jacc.org
Objectives: We sought to determine the potential of remote ischemic periconditioning
(RIPC), and its combination with morphine, to reduce reperfusion injury in primary …

Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study

S Deftereos, G Giannopoulos, C Angelidis… - Circulation, 2015 - Am Heart Assoc
Background—Inflammatory processes have been identified as key mediators of the
deleterious effects of ischemia/reperfusion in ST-segment–elevation myocardial infarction …

Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study

S Deftereos, G Giannopoulos, C Kossyvakis… - Journal of the American …, 2012 - jacc.org
Objectives: The purpose of the present study was to test the potential of colchicine, an agent
with potent anti-inflammatory action, to reduce atrial fibrillation (AF) recurrence after …

Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients

S Deftereos, G Giannopoulos, K Raisakis… - Journal of the American …, 2013 - jacc.org
Objectives: This study sought to test the hypothesis that colchicine treatment after
percutaneous coronary intervention (PCI) can lead to a decrease in in-stent restenosis (ISR) …